JP2025508016A5 - - Google Patents

Info

Publication number
JP2025508016A5
JP2025508016A5 JP2024552797A JP2024552797A JP2025508016A5 JP 2025508016 A5 JP2025508016 A5 JP 2025508016A5 JP 2024552797 A JP2024552797 A JP 2024552797A JP 2024552797 A JP2024552797 A JP 2024552797A JP 2025508016 A5 JP2025508016 A5 JP 2025508016A5
Authority
JP
Japan
Prior art keywords
cancer
pharmaceutical composition
kit
leukemia
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024552797A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025508016A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/063669 external-priority patent/WO2023168394A1/en
Publication of JP2025508016A publication Critical patent/JP2025508016A/ja
Publication of JP2025508016A5 publication Critical patent/JP2025508016A5/ja
Pending legal-status Critical Current

Links

JP2024552797A 2022-03-04 2023-03-03 Ｉａｐアンタゴニスト化合物を用いたがんの治療方法及び併用療法 Pending JP2025508016A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263316680P 2022-03-04 2022-03-04
US63/316,680 2022-03-04
PCT/US2023/063669 WO2023168394A1 (en) 2022-03-04 2023-03-03 Methods of treating cancer with iap antagonist compounds and combination therapies

Publications (2)

Publication Number Publication Date
JP2025508016A JP2025508016A (ja) 2025-03-21
JP2025508016A5 true JP2025508016A5 (OSRAM) 2026-03-12

Family

ID=85792184

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024552797A Pending JP2025508016A (ja) 2022-03-04 2023-03-03 Ｉａｐアンタゴニスト化合物を用いたがんの治療方法及び併用療法

Country Status (7)

Country Link
US (1) US20250186451A1 (OSRAM)
EP (1) EP4486352A1 (OSRAM)
JP (1) JP2025508016A (OSRAM)
KR (1) KR20240156407A (OSRAM)
AU (1) AU2023229084A1 (OSRAM)
TW (1) TW202345849A (OSRAM)
WO (1) WO2023168394A1 (OSRAM)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR122022015241B1 (pt) 2013-12-20 2023-09-26 Astex Therapeutics Limited Compostos heterocíclicos bicíclicos intermediários para a preparação de um composto de fórmula (i)
CN120379671A (zh) * 2022-10-18 2025-07-25 辉瑞公司 用于治疗癌症的化合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
BR122022015241B1 (pt) 2013-12-20 2023-09-26 Astex Therapeutics Limited Compostos heterocíclicos bicíclicos intermediários para a preparação de um composto de fórmula (i)
GB201919219D0 (en) * 2019-12-23 2020-02-05 Otsuka Pharma Co Ltd Cancer biomarkers

Similar Documents

Publication Publication Date Title
JP2025508016A5 (OSRAM)
JP2022537551A5 (OSRAM)
CN113768933B (zh) Parp抑制剂用于治疗化疗耐药的卵巢癌或乳腺癌的用途
US20080213399A1 (en) Combination Therapies Using Hdac Inhibitors
JP2011503063A5 (OSRAM)
RU2008122358A (ru) Лекарственные формы, содержащие ag013736
JP2006523216A5 (OSRAM)
JP2005527599A5 (OSRAM)
RU2734260C2 (ru) Применение производных хинолина для лечения рака пищевода, а также способ лечения, фармацевтическая композиция и набор с их использованием
JP2023548055A5 (OSRAM)
RU2005141408A (ru) Комбинированное применение эктеинасцидина-743 и содержащих платину противоопухолевых соединений
JP2024524461A5 (OSRAM)
JP2024502446A5 (OSRAM)
JP2007500134A5 (OSRAM)
JP2023505301A5 (OSRAM)
JP2023540206A5 (OSRAM)
JP5210888B2 (ja) 黒色腫の治療のためのガリウム（ｉｉｉ）錯体の使用
JP2025509278A5 (OSRAM)
JP2024527974A5 (OSRAM)
JP2024506385A5 (OSRAM)
JP7278405B2 (ja) 小細胞肺がんの治療におけるキアウラニブの使用
JP2006508118A5 (OSRAM)
JP2020520385A5 (OSRAM)
JP2021511352A5 (OSRAM)
WO2019201882A1 (en) Combination therapy with a bet inhibitor and a proteasome inhibitor